Difference between revisions of "Sintilimab (Tyvyt)"
Jump to navigation
Jump to search
m |
|||
| Line 7: | Line 7: | ||
*[[Hodgkin lymphoma]] | *[[Hodgkin lymphoma]] | ||
*[[Non-small cell lung cancer]] | *[[Non-small cell lung cancer]] | ||
| + | **[[Non-small cell lung cancer, squamous]] | ||
==Also known as== | ==Also known as== | ||
| Line 21: | Line 22: | ||
[[Category:Hodgkin lymphoma medications]] | [[Category:Hodgkin lymphoma medications]] | ||
[[Category:Non-small cell lung cancer medications]] | [[Category:Non-small cell lung cancer medications]] | ||
| + | [[Category:Non-small cell lung cancer, squamous medications]] | ||
[[Category:NMPA approved drugs]] | [[Category:NMPA approved drugs]] | ||
[[Category:PMDA approved drugs]] | [[Category:PMDA approved drugs]] | ||
Revision as of 12:47, 25 December 2022
Mechanism of action
From NCI Drug Dictionary: A recombinant human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1; PDCD1; PD1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, sintilimab binds to PD-1 and inhibits the binding of PD-1 to the PD-1 ligands programmed cell death-1 ligand 1 (PD-L1), and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of both T cells and T-cell-mediated immune responses against tumor cells.
Diseases for which it is used
- Esophageal squamous cell carcinoma
- Hepatocellular carcinoma
- Hodgkin lymphoma
- Non-small cell lung cancer
Also known as
- Code name: IBI 308
- Brand name: Tyvyt